Form 8-K - Current report:
SEC Accession No. 0001193125-25-179958
Filing Date
2025-08-13
Accepted
2025-08-13 17:05:59
Documents
19
Period of Report
2025-08-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d153873d8k.htm   iXBRL 8-K 34633
2 EX-1.1 d153873dex11.htm EX-1.1 252678
3 EX-4.1 d153873dex41.htm EX-4.1 68447
4 EX-5.1 d153873dex51.htm EX-5.1 9061
5 EX-99.1 d153873dex991.htm EX-99.1 8779
6 EX-99.2 d153873dex992.htm EX-99.2 9465
10 GRAPHIC g153873g0813185359550.jpg GRAPHIC 7592
11 GRAPHIC g153873g0813185439840.jpg GRAPHIC 7592
  Complete submission text file 0001193125-25-179958.txt   627362

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA cmpx-20250812.xsd EX-101.SCH 2876
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpx-20250812_lab.xml EX-101.LAB 18736
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpx-20250812_pre.xml EX-101.PRE 11724
22 EXTRACTED XBRL INSTANCE DOCUMENT d153873d8k_htm.xml XML 3802
Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 617-500-8099
Compass Therapeutics, Inc. (Filer) CIK: 0001738021 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39696 | Film No.: 251212746
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)